TITLE

COMPANY SPOTLIGHT -- Bayer Schering

PUB. DATE
November 2010
SOURCE
PharmaWatch: CNS;Nov2010, Vol. 9 Issue 11, p19
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article features Bayer Schering Pharma AG. It relates that the pharmaceutical company is a research-based company which engaged in the manufacturing, developing, and marketing of pharmaceutical products. It says that the company focuses in four businesses including diagnostic imaging, general medicine, and women's health. Moreover, the company has announced its launch of betaferon and gadovist imaging agents in treating multiple sclerosis in China.
ACCESSION #
55155982

 

Related Articles

  • CNS News Round-Up.  // PharmaWatch: Monthly Review;Jan2010, Vol. 9 Issue 1, p15 

    The article provides updates regarding the developments of the pharmaceutical industry worldwide. Bayer Schering Pharma AG has won the Chinese approval for its multiple sclerosis drug. Meanwhile, Addex Pharmaceuticals Inc. has extended its research collaboration with Merck & Co. Inc. Moreover,...

  • Bayer acquires manufacturing facility from Novartis.  // PharmaWatch: Biotechnology;Nov2007, Vol. 6 Issue 11, p25 

    The article reports that Bayer Schering Pharma AG has purchased a manufacturing facility from Novartis AG in Emeryville, California. This move is part of a deal to acquire the rights to multiple sclerosis drug Betaseron. Bayer Schering will manufacture and retain full control of all...

  • Schering AG SWOT Analysis.  // Schering AG SWOT Analysis;Jun2007, p1 

    A company profile of Bayer Schering Pharma AG, a global pharmaceutical company that is active in areas such as gynecology, andrology, oncology, diagnostic imaging and specialized therapeutics, is presented. An overview of the company is given, along with key facts including contact information,...

  • Company Overview.  // Schering AG SWOT Analysis;Jun2007, p4 

    An overview of Bayer Schering Pharma AG, a global pharmaceutical company that is active in areas such as gynecology, andrology, oncology, diagnostic imaging and specialized therapeutics, is presented. Data is included on revenues generated in the fiscal year ended December 2006, the number of...

  • Schering renamed.  // European Pharmaceutical Executive;Feb/Mar2007, p10 

    The article reports on Germany-based Schering AG's decision to change its name to Bayer Schering Pharma AG. The necessary entry in the commercial register took effect on December 29, 2006. The article also reports that the new logo has been mounted on Bayer Schering Pharma's headquarters in...

  • TOP 20 PHARMA: #15 BAYER SCHERING.  // Contract Pharma;2009, Vol. 11 Issue 6, p84 

    The article profiles Bayer Schering Pharma AG, the rank 15 among the top 20 pharmaceutical companies based in Leverkusen, Germany. It notes that it was founded in 1971 and handles 108,600 employees. It mentions its plan to strengthen its research and development initiative in 2009 through its 4...

  • Schering and Bayer seal drug ownership agreement. Chynoweth, Emma // ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p33 

    This article reports that Bayer Schering Pharma and Novartis have settled a dispute over U.S. production of the interferon-based multiple sclerosis treatment Betaseron, sold in the U.S. as Betaferon. The deal sees Bayer Schering Pharma acquiring most of Novartis' Emeryville, California, site,...

  • Bayer wins Chinese approval for multiple sclerosis drug.  // PharmaWatch: CNS;Jan2010, Vol. 9 Issue 1, p4 

    The article reports that Bayer Schering Pharma AG has reported that the State Food and Drug Administration of China has approved Betaferon therapy for patients with relapsing-remitting multiple sclerosis (MS). Bayer has planned to launch Betaferon in the Chinese market by mid-2010. The approval...

  • Alemtuzumab In Phase III Against Rebif In MS.  // Bioworld Week;10/1/2007, Vol. 15 Issue 40, p5 

    The article reports on the comparison of Alemtuzumab and Rebif efficacy in multiple sclerosis patients for the first of two Phase III studies conducted by Genzyme Corp. of Cambridge, Massachusetts and partner Bayer Schering Pharma AG of Berlin, Germany. Alemtuzumab will be given in two annual...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics